A5001930238- Cancer Immunotherapy and Biomarkers
- Immune Cell Function and Interaction
- Immunotherapy and Immune Responses
- Inflammasome and immune disorders
- Adenosine and Purinergic Signaling
- Autoimmune and Inflammatory Disorders Research
- Cancer Mechanisms and Therapy
- Pharmacological Effects of Natural Compounds
- Galectins and Cancer Biology
- Sex and Gender in Healthcare
- Interdisciplinary Research and Collaboration
- Cancer-related molecular mechanisms research
- Extracellular vesicles in disease
- Advanced biosensing and bioanalysis techniques
- Nuclear Receptors and Signaling
- RNA Research and Splicing
- RNA modifications and cancer
- Viral Infections and Immunology Research
- Career Development and Diversity
University of California, San Francisco
2021-2025
Gender inequities persist in science, with women encountering significant barriers at various career stages, particularly fields such as Immunology. This article highlights the work of Immunologists for Equity (IgEquity), a trainee-led organization within ImmunoX Program University California, San Francisco (UCSF), which is committed to addressing these disparities. Through initiatives focused on community building, mentorship, outreach and advocacy, IgEquity seeks advance gender equity...
Abstract Immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway are thought to primarily function through enhancement of CD8+ T cell-mediated killing tumor cells, which requires recognition MHC-I-tumor antigen peptide complexes on cells by T-cell receptor. Therefore, a proposed mechanism resistance is downregulation MHC-I cell surface. However, previous studies using MHC-I-deficient mouse models have shown evidence continued inhibition growth these inhibitors. The mechanisms...
Abstract Poliovirus receptor-related 2 (PVRL2, also known as nectin-2 or CD112) is believed to act an immune checkpoint protein in cancer; however, most insight into its role inferred from studies on receptor, poliovirus receptor (PVR)-related immunoglobulin domain (PVRIG, CD112R). Here, we study PVRL2 itself. levels were found be high tumor cells and tumor-derived exosomes. Deletion of multiple syngeneic mouse models cancer showed a dramatic reduction growth that was dependent. This effect...
Abstract In recent years, PVRL2 (also known as Nectin-2 or CD112), a member of the Nectin family, has emerged crucial regulator anti-tumor immune responses. interacts with co-inhibitory receptor PVRIG that is expressed on T cells and NK cells, inhibiting their function. This interaction thus become presumed mechanism for PVRL2’s immunoinhibitory Therapeutic development targeting pathway primarily focused PVRIG, two anti-PVRIG antibodies currently undergoing Phase 1/2 clinical trials...
<p>Supplementary Figure S1: Proteomic analysis identifies PVRL2 on tumor-derived exosomes.</p>
<p>Supplementary Figure S5: Combined loss of PVRL2 and PVR does not further inhibit tumor growth.</p>
<p>Supplementary Figure S3: PVRL2 regulates CD8 T cell and NK activation.</p>
<p>Supplementary Table S1: Statistical analysis comparing the areas under curves (AUC) of tumor growth data between groups using an unpaired Student’s t test.</p>
<p>Supplementary Figure S5: Combined loss of PVRL2 and PVR does not further inhibit tumor growth.</p>
<p>Supplementary Figure S1: Proteomic analysis identifies PVRL2 on tumor-derived exosomes.</p>
<div>Abstract<p>Poliovirus receptor-related 2 (PVRL2, also known as nectin-2 or CD112) is believed to act an immune checkpoint protein in cancer; however, most insight into its role inferred from studies on receptor, poliovirus receptor (PVR)-related immunoglobulin domain (PVRIG, CD112R). Here, we study PVRL2 itself. levels were found be high tumor cells and tumor-derived exosomes. Deletion of multiple syngeneic mouse models cancer showed a dramatic reduction growth that was...
<p>Supplementary Figure S2: PVRL2 promotes tumor growth through an immune-dependent mechanism.</p>
<div>Abstract<p>Poliovirus receptor-related 2 (PVRL2, also known as nectin-2 or CD112) is believed to act an immune checkpoint protein in cancer; however, most insight into its role inferred from studies on receptor, poliovirus receptor (PVR)-related immunoglobulin domain (PVRIG, CD112R). Here, we study PVRL2 itself. levels were found be high tumor cells and tumor-derived exosomes. Deletion of multiple syngeneic mouse models cancer showed a dramatic reduction growth that was...
<p>Supplementary Figure S4: PVRL2 functions independently of PVRIG and TIGIT pathways.</p>
<p>Supplementary Table S1: Statistical analysis comparing the areas under curves (AUC) of tumor growth data between groups using an unpaired Student’s t test.</p>
<p>Supplementary Figure S4: PVRL2 functions independently of PVRIG and TIGIT pathways.</p>
<p>Supplementary Figure S3: PVRL2 regulates CD8 T cell and NK activation.</p>
<p>Supplementary Figure S2: PVRL2 promotes tumor growth through an immune-dependent mechanism.</p>
Abstract PVRL2 is believed to act as an immune checkpoint protein in cancer; however, most insight into PVRL2’s role inferred from studies on its known receptor PVRIG. Here, we directly study PVRL2. levels are high tumor cells and tumor-derived exosomes. Deletion of multiple syngeneic mouse models cancer shows a dramatic reduction growth that dependent. This effect can be even greater than seen with deletion PD-L1. functions by suppressing CD8 T NK the microenvironment. Unexpectedly, loss...
Abstract BACKGROUND To develop effective immunotherapy for gliomas, it is crucial to expand the repertoire of targetable antigens. Recent studies have suggested that alternative splicing (AS), or its deriving tumor-specific junctions (“neojunctions”), could generate cryptic amino acid sequences can be a source neoantigens. In this study, we investigated neojunctions based on multifaceted transcriptomic and proteomic analyses, seeking potential cell surface antigens may targeted by CAR....